FY2025 · ended Dec 31, 2025 · Revenue $372.07M, +123.4% YoY · Filed Feb 25, 2026
Arcutis Biotherapeutics, Inc. (ARQT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $372.1 million and a net loss of $16.1 million. Free cash flow was -$6.3 million. As of Sep 30, 2026 it held $259.5 million in cash and investments and $114.6 million in total debt.
Revenue (TTM)
$506.68M
+61.4% vs year-ago TTM
Net income (TTM)
$29.91M
+167.5% vs year-ago TTM
Operating cash flow (TTM)
$59.96M
+284.2% vs year-ago TTM
Free cash flow (TTM)
$59.71M
+279.6% vs year-ago TTM
EPS (TTM)
$0.22
+163.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
124.03M
+4.5% vs prior year
Net cash
$144.84M
as of Sep 30, 2026
Operating margin
6.9%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ARQT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westlake Village, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1787306
- Former names
- Arcutis, Inc. (until Sep 9, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $372.1M | $166.5M | $29.2M | $3.7M | — |
| Operating income | -$12.2M | -$128.4M | -$241.1M | -$301.6M | -$206.5M |
| Net income | -$16.1M | -$140.0M | -$262.1M | -$311.5M | -$206.4M |
| Diluted EPS | -$0.13 | -$1.16 | -$3.78 | -$5.66 | -$4.18 |
| Operating cash flow | -$5.6M | -$112.2M | -$247.1M | -$257.7M | -$174.6M |
| Free cash flow | -$6.3M | -$112.3M | -$247.5M | -$258.0M | -$175.6M |
| Total assets | $433.0M | $348.9M | $341.4M | $449.3M | $408.2M |
| Total liabilities | $243.5M | $191.3M | $252.7M | $239.7M | $110.5M |
| Stockholders' equity | $189.5M | $157.5M | $88.7M | $209.6M | $297.7M |
| Cash and investments | $221.0M | $228.0M | $271.9M | $409.6M | $387.1M |
| Total debt | $114.5M | $110.6M | $205.9M | $202.5M | $77.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 28, 2026 | Oct 23, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 5, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 16, 2026 | Jul 15, 2026 |
All 866 Arcutis Biotherapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.